Quick summary: Many mental health patients who have exhausted standard treatments carry a burden of self-doubt and anticipated judgement that shapes what they say, and do not say, in clinical appointments. Stigma operates not only in public attitudes but inside consulting rooms, where patients may avoid raising legitimate questions about legal treatment options such as prescribed medical cannabis. Clinicians who can hold complexity without retreating into reflex caution are better placed to support patients who still have reason to hope.
Few experiences are more quietly exhausting than feeling as though you have run through every option and are still unwell. In psychiatry, I meet people who are not simply distressed by their symptoms. Often, they are also worn down by the experience of having tried, hoped, adjusted, endured side effects, waited, tried again, and still not found the kind of relief they were promised. By the time some patients arrive in front of a specialist, they are carrying more than anxiety, depression, insomnia, or emotional dysregulation. Alongside those symptoms sits a different burden: disappointment, self-doubt, and the creeping fear that they may be becoming the sort of patient for whom nothing really works.
For many people, this part of mental health care is not discussed enough. Clinical language can make it sound neat. Real life is rarely neat. Repeated treatment changes do not just leave a paper trail. They shape how someone sees themselves. They can leave a person feeling as though they have failed treatment, when in reality treatment has failed to meet their needs. Jon Robson, CEO of Mamedica, the medical cannabis healthcare platform, supporting more than 12,000 patients nationwide, has said “there is a real human cost when people start censoring themselves in the consulting room. Once somebody feels they have tried everything, shutting down a discussion through stigma can leave them feeling even more isolated and even less hopeful.”
Recent UK research into treatment-resistant depression captures some of this weight. In a mixed-methods study of more than 5,000 patients with major depressive disorder within one large NHS trust, nearly 48% met criteria for treatment-resistant depression, while 36.93% had tried four or more antidepressant treatments. The authors also described the cumulative burden created by repeated treatment failures, which many patients and clinicians will immediately recognise as more than a technical problem. It is emotional, relational, and deeply destabilising. Simultaneously, demand across mental health services remains immense. NHS England Digital reported 2.24 million people were in contact with mental health services at the end of January 2026, with 485,675 new referrals received during that month alone.
Under those conditions, people do not make decisions about care in a vacuum. They make them while tired, frightened, and often ashamed. I agree with Jon Robson that “medical cannabis should be discussed on clinical terms, not cultural ones. Patients deserve room to ask difficult questions about a legal treatment option without feeling they are stepping outside the boundaries of serious care.” Stigma has a great deal to do with that and usually, when people hear the word stigma, they picture public attitudes or media stereotypes. Yet stigma also works in quieter ways. It can make patients edit what they say in appointments. It can make them avoid questions they fear will invite judgement. It can make them hesitate before mentioning something they have read about, wondered about, or even already tried. A 2024 scoping review noted that stigma surrounding mental health disorders is linked to delayed help-seeking, limited access to health services, suboptimal treatment, and poorer outcomes.
Once someone has the sense that they have “tried everything”, this becomes even more psychologically charged. Hope starts to feel dangerous. Curiosity can feel embarrassing. Asking about another option may feel less like self-advocacy and more like admitting desperation. This is one reason conversations around medical cannabis need more care and more honesty than they often receive.
Prescribed medical cannabis is not interchangeable with recreational cannabis use, but those two ideas are still regularly collapsed into one another in public discussion. As a result, some patients approach the subject with visible discomfort, as though even raising it might make them appear unserious, reckless, or naïve. For somebody who already feels worn down by years of trying to get better, this sense of anticipated judgement can be enough to shut the conversation down before it has properly begun.
None of this means medical cannabis is suitable for everyone. But, observational data from the UK add to the case for having that conversation properly. In a case series from the UK Medical Cannabis Registry, patients treated for generalised anxiety disorder showed improvements in anxiety, sleep quality, and health-related quality of life. More recently, a two-year depression case series from the same registry reported statistically and clinically significant improvements in depression, anxiety, sleep quality, and quality of life, while also making clear that no causal conclusions can be drawn from observational data alone.
Good psychiatric care should not confuse caution with shutdown. A thoughtful conversation about a culturally loaded treatment is still a clinical conversation. It should involve risk, uncertainty, context, history, exclusion criteria, and honest discussion. It should not be replaced by reflex, embarrassment, or moral shorthand.Patients in this position need more room to speak honestly without feeling judged for what they ask, what they fear, or what they still hope for. They need clinicians who can tolerate complexity without retreating into simplification. They need care that recognises how exhausting it is to keep trying.
Mental health treatment is difficult enough without stigma narrowing the conversation before it begins. Jon and I both agree, “nobody is served by making patients feel embarrassed for still hoping something might help. The right response is not judgement. It is a calm, properly informed discussion about whether a treatment is appropriate for that individual.” Once a person feels they have tried everything, what happens next is shaped not only by evidence and diagnosis, but by whether they still feel allowed to ask difficult questions. In psychiatry, we should protect that space far more carefully than we do.
Dr Imogen Kretzschmar is a consultant psychiatrist at Mamedica, a UK digital healthcare platform specialising in legally prescribed medical cannabis. Her background is in forensic psychiatry, with research experience at King’s College London.